---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-191500"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:52:35.947484+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology licenses three clinical-stage masked T-cell engagers from Sanofi for $100M upfront

## Summary
- Upfront payment of $100M plus $75M escrowed milestone for SAR446368 (AMX-525) first-in-human dosing by 2026.
- Eligible for up to $323M in development/regulatory milestones and up to $1.488B in commercial sales milestones.
- License covers SAR446309, SAR446329, and SAR446368 (AMX-525) masked T-cell engagers and protease-cleavable masking platform.
- Exclusive worldwide license for oncology and infectious disease, excluding ophthalmology; low single-digit to low double-digit tiered royalties.
- Closing contingent on expiration or termination of applicable HSR waiting period.

## SEC filing metadata
- accession: 0001193125-24-191500
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312524191500/0001193125-24-191500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312524191500/d880653d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-191500
- JSON: https://secwatch.observer/filing/0001193125-24-191500.json
- Plain text: https://secwatch.observer/filing/0001193125-24-191500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.